Guangjia Technology

Biodata

Feature	Information
Name	Guangjia Technology
Alias(es)	光甲科技
Industry	Human hibernation technology, biomedical devices, innovative drugs, and technology investment
Founder	Chen Yuanguang
Co-founder	Lin Jia
Key personnel	Chen Yuanguang — Chairman and Chief Technology Officer; Lin Jia — co-founder and shareholder; Sun Renjie — early recruit involved in operations 55 89 92
Affiliation	Guangjia Group
Status	Active; publicly listed on the STAR Market 92 334
First Appearance	Chapter 53

Corporate Development

Event	Chapter	Details
Founded	53	Chen Yuanguang established the company in a Caohejing laboratory to develop human hibernation technology. He described the name as “the armor I’m building for everyone.” Lin Jia took responsibility for registration and early administrative work.
Began operations	55	After Sun Renjie was recruited, Guangjia Technology assembled its first fifteen employees, including finance and legal personnel, and formally began operating.
External financing	66, 82	The company secured 1.5 billion RMB in external funding before later raising a $2 billion Series A round.
Human-hibernation breakthrough	88	The company achieved a method allowing people to automatically leave hibernation within half an hour.
STAR Market listing	92	Guangjia Technology received approval to list on the STAR Market; Chen Yuanguang attended the listing ceremony as chairman.
Post-listing valuation	93, 108	Its market capitalization held above 500 billion RMB after listing, making it the STAR Market’s highest-valued company at the time.
Expansion beyond hibernation	113, 115	The company licensed aerospace-derived high-fidelity audio technology to Xiaomi for automotive use and began pursuing external investments.
Shift toward drug acquisitions	334, 335	With human-hibernation equipment providing stable cash flow, the company increasingly acquired and financed innovative-drug firms rather than relying on internal drug R&D.
U.S. health-and-wellness project	352	Guangjia Technology and China Life planned a high-end health-and-wellness center in Los Angeles, with the Guangjia brand viewed as central to its appeal.

History

Founding and Early Operations

Chen Yuanguang rejected Lin Jia’s proposed path of vaccine services and AI pharmaceutical R&D, instead committing Guangjia Technology to human hibernation technology. Lin Jia considered the project commercially risky but supported the decision, handling registration and helping build the initial organization. 53

The firm’s first team consisted of fifteen employees. Sun Renjie used his biomedical-industry network to assist recruitment, while headhunters supplied key finance and legal personnel. 55

Financing and Listing

Investor confidence grew rapidly because of Chen Yuanguang’s reputation, the company’s state-owned-assets background, and the perceived monopoly potential of human hibernation technology. Following external financing and a $2 billion Series A round, its listing became widely anticipated. 66 82

Guangjia Technology was approved to list on the STAR Market in April. Its listing attracted major media, financial institutions, government representatives, and overseas attention because human hibernation was regarded as a unique technology with broad applications. 92

Later Business Direction

Chen Yuanguang distinguished Guangjia Technology from Guangjia Aerospace by defining the former as a conventional profit-seeking company responsible for financing, investment, operations, R&D, and marketing. 115

After listing, management authority was gradually delegated to professional managers. The company developed into a major innovative-drug enterprise whose human-hibernation business supplied stable cash flow for acquisitions, drug-development funding, and investment activity. 334

Technology and Business

Human Hibernation Technology

Guangjia Technology’s core product is human hibernation equipment, a technology that acts directly on the human brain and is treated as a monopoly business. 87 433

• Early trial samples showed no adverse reactions, with the estimated probability of adverse effects stated to be below one in 100,000. 87
• The company conducted clinical trials in China and overseas, including Europe, Southeast Asia, and North America. 92 101
• A major breakthrough enabled subjects to automatically end hibernation in less than half an hour. 88
• The technology’s medical and restorative effects drew intense public interest, though online users also fabricated trial experiences for attention. 88
• Chen Yuanguang deliberately chose not to release more advanced versions capable of freezing people for one or two years, believing widespread lifespan extension could make society more rigid and reduce class mobility. 335

Innovative-Drug Investment and Acquisitions

Guangjia Technology uses its cash flow and relationships with hospitals and regulators to acquire innovative-drug companies at low valuations, continue their R&D, and bring products to market. 334

• The company acquired Sino Medical, a Hong Kong-listed developer of small-nucleic-acid drugs, for less than $20 million after the target had spent roughly $50 million on R&D. 334
• Its investment decisions reportedly achieve a success rate of about 50%, compared with about 10% for general innovative-drug investment capital. 334
• Investment became the company’s largest source of profit, leading investors to joke that its true main business was capital operations rather than biomedical devices. 334
• High bonuses for investment recommendations diverted some R&D staff away from internal research, leaving the company’s self-developed drug pipeline comparatively weak. 335

Automotive Audio Technology

Guangjia Technology commercialized a high-fidelity mono sound system derived from aerospace communications research. Chen Yuanguang stated that its signal-transmission precision made it suitable for automotive speakers. 113

• Xiaomi and Guangjia Technology agreed to a five-year exclusive automotive technology license. 113
• The agreement included a 500 million RMB transaction for a 20% stake. 113
• Xiaomi planned to demonstrate the audio system in its stores before the launch of Xiaomi Auto. 113
• The technology was still a laboratory product at the time of the agreement, with mass-production timing undetermined. 113

International Operations and Restrictions

Guangjia Technology pursued overseas clinical trials and was expected to establish branches in Europe, South Africa, and Southeast Asia, where it could retain most profits directly. 87

North America was more difficult due to Washington’s scrutiny of Chinese companies and the sensitivity of a technology involving the human brain. Goldman Sachs sought a separate cooperation model to facilitate entry into the U.S. market. 87

• American political figures considered whether human hibernation technology should be imported despite broader concerns about Chinese technology. 93
• The United States later considered expanding technology restrictions to include Guangjia Technology and its products. 108
• Lin Jia disclosed that the White House had prohibited Guangjia Technology’s technology from entering the American market. 155
• Despite restrictions, Guangjia Technology and China Life planned a high-end health-and-wellness center in Los Angeles, where the Guangjia brand was considered recognizable among wealthy U.S. consumers. 352

Relationships

• Chen Yuanguang — Founder, chairman, and CTO; set the company’s human-hibernation direction and retained control of its technological strategy. 53 92 115
• Lin Jia — Co-founder, early organizer, spokesperson, and holder of 5% original shares with voting rights. 53 69 88 89
• Sun Renjie — Early employee recruited by Chen Yuanguang; helped assemble the initial team through his biomedical-industry connections. 55
• CICC — Listing sponsor for Guangjia Technology’s STAR Market IPO. 88
• Xiaomi — Automotive technology partner under an exclusive licensing arrangement for Guangjia Technology’s high-fidelity sound equipment. 113
• China Life — Partner in the planned Los Angeles high-end health-and-wellness center. 352
• Goldman Sachs — Investor and prospective North American cooperation partner seeking to promote the adoption of human hibernation technology in the United States. 78 87